Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy
- PMID: 20647570
- DOI: 10.1182/blood-2010-05-284919
Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy
Abstract
Fetal and neonatal immune thrombocytopenia (FNIT) is a severe bleeding disorder in which maternal antibodies cross the placenta and destroy fetal/neonatal platelets. It has been demonstrated that the neonatal Fc receptor (FcRn) regulates immunoglobulin G (IgG) homeostasis and plays an important role in transplacental IgG transport. However, the role of FcRn in the pathogenesis and therapy of FNIT has not been studied. Here, we developed an animal model of FNIT using combined β3 integrin-deficient and FcRn-deficient (β3(-/-)FcRn(-/-)) mice. We found that β3(-/-)FcRn(-/-) mice are immunoresponsive to β3(+/+)FcRn(-/-) platelets. The generated antibodies were β3 integrin specific and were maintained at levels that efficiently induced thrombocytopenia in adult β3(+/+)FcRn(-/-) mice. FNIT was observed when immunized β3(-/-)FcRn(+/+) females were bred with β3(+/+)FcRn(+/+) males, while no FNIT occurred in β3(-/-)FcRn(-/-) females bred with β3(+/+)FcRn(-/-) males, suggesting that FcRn is indispensable for the induction of FNIT. We further demonstrated that fetal FcRn was responsible for the transplacental transport of various IgG isotypes. We found that anti-FcRn antibody and intravenous IgG prevented FNIT, and that intravenous IgG ameliorated FNIT through both FcRn-dependent and -independent pathways. Our data suggest that targeting FcRn may be a potential therapy for human FNIT as well as other maternal pathogenic antibody-mediated diseases.
Comment in
-
FNAIT: the fetus pleads guilty!Blood. 2010 Nov 4;116(18):3384-6. doi: 10.1182/blood-2010-08-299404. Blood. 2010. PMID: 21051565
Similar articles
-
The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies.J Clin Invest. 2011 Nov;121(11):4537-47. doi: 10.1172/JCI57850. Epub 2011 Oct 24. J Clin Invest. 2011. PMID: 22019589 Free PMC article.
-
New developments in fetal and neonatal alloimmune thrombocytopenia.Am J Obstet Gynecol. 2021 Aug;225(2):120-127. doi: 10.1016/j.ajog.2021.04.211. Epub 2021 Apr 8. Am J Obstet Gynecol. 2021. PMID: 33839095 Review.
-
Maternal anti-platelet β3 integrins impair angiogenesis and cause intracranial hemorrhage.J Clin Invest. 2015 Apr;125(4):1545-56. doi: 10.1172/JCI77820. Epub 2015 Mar 16. J Clin Invest. 2015. PMID: 25774504 Free PMC article.
-
FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies.Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12943-12951. doi: 10.1073/pnas.2004325117. Epub 2020 May 27. Proc Natl Acad Sci U S A. 2020. PMID: 32461366 Free PMC article.
-
Predicting risk severity and response of fetal neonatal alloimmune thrombocytopenia.Br J Haematol. 2013 Aug;162(3):304-12. doi: 10.1111/bjh.12372. Epub 2013 May 14. Br J Haematol. 2013. PMID: 23672281 Review.
Cited by
-
Current Insights Into K-associated Fetal Anemia and Potential Treatment Strategies for Sensitized Pregnancies.Transfus Med Rev. 2024 Jan;38(1):150779. doi: 10.1016/j.tmrv.2023.150779. Epub 2023 Oct 15. Transfus Med Rev. 2024. PMID: 37926651 Review.
-
The therapeutic age of the neonatal Fc receptor.Nat Rev Immunol. 2023 Jul;23(7):415-432. doi: 10.1038/s41577-022-00821-1. Epub 2023 Feb 1. Nat Rev Immunol. 2023. PMID: 36726033 Free PMC article. Review.
-
Chronic Inflammatory Placental Disorders Associated With Recurrent Adverse Pregnancy Outcome.Front Immunol. 2022 Apr 22;13:825075. doi: 10.3389/fimmu.2022.825075. eCollection 2022. Front Immunol. 2022. PMID: 35529853 Free PMC article. Review.
-
Blocking Placental Class G Immunoglobulin Transfer Prevents NMDA Receptor Antibody Effects in Newborn Mice.Neurol Neuroimmunol Neuroinflamm. 2021 Sep 27;8(6):e1061. doi: 10.1212/NXI.0000000000001061. Print 2021 Nov. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34580181 Free PMC article.
-
Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia.Blood Adv. 2021 Sep 28;5(18):3552-3562. doi: 10.1182/bloodadvances.2021004371. Blood Adv. 2021. PMID: 34470046 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases